Suppr超能文献

在一名肝素诱导的血小板减少症(HIT II)患者中,使用重组水蛭素(lepirudin)作为抗凝剂进行持续血液滤过。

Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II).

作者信息

Schneider T, Heuer B, Deller A, Boesken W H

机构信息

II. Department of Internal Medicine, Krankenhaus der Barmherzigen Brüder, Trier, Federal Republic of Germany.

出版信息

Wien Klin Wochenschr. 2000 Jun 16;112(12):552-5.

Abstract

A 60-year-old man was admitted to the hospital with aortic dissection. An operative excision and replacement with a Y-graft was performed. Postoperatively he developed multiple organ dysfunction and required intermittent haemofiltration (anticoagulation with heparin). An ischemia of the left leg occurred at the third postoperative day. The initial platelet count was 99,000/microliter. Continuous haemofiltration (CVVH) was started three days later. Thrombotic obstructions of haemodialysis filters and catheters occurred frequently and heparin-induced thrombocytopenia (HIT II) was suspected. Antibodies against heparin were found in the HIPA test. Despite heparin free citrate dialysis and anticoagulation with danaparoid thrombotic obstructions of filters and catheters continued. Therefore the anticoagulation therapy during CVVH was changed to recombinant hirudin (lepirudin). Starting dose was a bolus of 0.01 mg/kg bw followed by the same amount as maintenance dose per hour. Anticoagulation was adjusted to an increase of aPTT (activated partial thromboplastin time) to 1.5-2 times its normal value. A dose of 0.005 mg/kg bw/h lepirudin was sufficient to maintain adequate anticoagulation. After changing to lepirudin no further catheter obstructions were observed and the platelets recovered slowly. Renal function improved and five weeks after admission endogenous creatinine clearance showed a value of 25 ml/min. We conclude that lepirudin is an effective anticoagulant during CVVH in patients with HIT II. In partly permeable polysulfon filters a dose of 0.005 mg/kg bw/h lepirudin is sufficient to maintain adequate anticoagulation. Monitoring anticoagulation by measuring the increase of aPTT (factor 1.5-2.0) seems to be safe. However, optimally the r-hirudin concentration should be measured directly using the Ecarin clotting time.

摘要

一名60岁男性因主动脉夹层入院。进行了手术切除并用Y型移植物进行置换。术后他出现多器官功能障碍,需要间歇性血液滤过(用肝素抗凝)。术后第三天出现左腿缺血。初始血小板计数为99,000/微升。三天后开始持续血液滤过(CVVH)。血液透析滤器和导管频繁出现血栓性阻塞,怀疑是肝素诱导的血小板减少症(HIT II)。在HIPA试验中发现了抗肝素抗体。尽管采用无肝素柠檬酸盐透析并用达那肝素抗凝,但滤器和导管的血栓性阻塞仍持续存在。因此,CVVH期间的抗凝治疗改为重组水蛭素(lepirudin)。起始剂量为0.01 mg/kg体重静脉推注,随后每小时给予相同剂量作为维持剂量。将抗凝调整至活化部分凝血活酶时间(aPTT)增加至其正常值的1.5 - 2倍。0.005 mg/kg体重/小时的lepirudin剂量足以维持充分的抗凝。改用lepirudin后未观察到进一步的导管阻塞,血小板缓慢恢复。肾功能改善,入院五周后内源性肌酐清除率显示为25 ml/min。我们得出结论,lepirudin是HIT II患者CVVH期间的一种有效抗凝剂。在部分可渗透的聚砜滤器中,0.005 mg/kg体重/小时的lepirudin剂量足以维持充分的抗凝。通过测量aPTT增加(系数1.5 - 2.0)来监测抗凝似乎是安全的。然而,最佳情况下应使用依卡瑞林凝血时间直接测量重组水蛭素浓度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验